6 november 2020: AP & T: First published: 27 July 2020

Aerobics gedurende 12 weken verbetert de cardiovasculaire conditie en verbetert fibrosevorming in de lever en de zogeheten metabole leververvetting. Het is een kleine studie maar de verbeteringen waren aanzienlijk. Echter wanneer de deelnemers weer stopten verdween de verbetering. Het lijkt dus beter om bij fibrose en levervetting veel te bewegen en te werken aan uw cardiovasculaire uithoudingsvermogen. Ik denk daarom dat het beste is om dat onder begeleiding te doen al kun je natuurlijk zelf ook een heleboel doen aan beweging en sporten. .

Het volledige studierapport is gratis in te zien en daarin kunt u meer lezen over de effecten van 12 weken aerobics enz.

Improvement in histological endpoints of MAFLD following a 12‐week aerobic exercise intervention

Philip O’Gorman

First published: 27 July 2020

https://doi.org/10.1111/apt.15989

Citations: 2

Philip O’Gorman and Sara Naimimohasses should be considered joint first authors and contributed equally to the study’s concept, design and experimental procedures.

The Handling Editor for this article was Professor Gideon Hirschfield, and it was accepted for publication after full peer‐review.

Funding information:

This study was funded, in full, by a grant held by Suzanne Norris from the Health Research Board, Ireland (grant number: HRA‐POR‐2015‐1185). Philip O’Gorman was funded through this grant for his PhD studentship.

Summary

Background

Lifestyle interventions are the primary treatment for metabolic (dysfunction) associated fatty liver disease (MAFLD). However, the histological and cardiometabolic effects of aerobic exercise in MAFLD remain unclear.

Aims

To assess the effects of a 12‐week aerobic exercise intervention on histological and cardiometabolic endpoints in MAFLD.

Methods

Patients with biopsy‐confirmed MAFLD participated in a 12‐week aerobic exercise intervention. Liver histology, cardiorespiratory fitness (estimated V̇O2max), physical activity, anthropometry and biochemical markers were assessed at baseline, intervention completion, and 12 and 52 weeks after intervention completion.

Results

Twenty‐four patients completed the exercise intervention (exercise group n = 16, control group n = 8). In the exercise group, 12 weeks of aerobic exercise reduced fibrosis and hepatocyte ballooning by one stage in 58% (P = 0.034) and 67% (P = 0.020) of patients, with no changes in steatosis (P = 1.000), lobular inflammation (P = 0.739) or NAFLD activity score (P = 0.172). Estimated V̇O2max increased by 17% compared to the control group (P = 0.027) but this level of improvement was not maintained at 12 or 52 weeks after the intervention. Patients with fibrosis and ballooning improvement increased estimated V̇O2max by 25% (P = 0.020) and 26% (P = 0.010), respectively. Anthropometric reductions including body mass (P = 0.038), waist circumference (P = 0.015) and fat mass (P = 0.007) were also observed, but no patient achieved 7%‐10% weight loss.

Conclusion

This study highlights the potential benefits of a 12‐week aerobic exercise intervention in improving histological endpoints of MAFLD. The development of strategies to ensure continued engagement in aerobic exercise in MAFLD are needed.

aerobics, fibrose, leververvetting, cardiovasculaire conditie, preventie, metabole geassocieerde leververvetting (MAFLD)